Here’s what we know so far:
How did the “double mutation” variant emerge?
The new variant, called B.1.617, was initially detected in India with two mutations -- the E484Q and L452R. It was first reported late last year by a scientist in India and more details were presented before the WHO on Monday, according to Van Kerkhove.
Viruses mutate all the time, as part of evolutionary biology. Some mutations weaken the virus while others may make it stronger, enabling it to proliferate faster or cause more infections.
India’s health ministry first acknowledged the presence of such a “double mutant” at the end of March, but has downplayed it since. While it’s a variant of interest, it “has not been stamped as a ‘variant of concern’ so as to say that it is more lethal or more infectious,” Aparna Mukherjee, a scientist at the Indian Council of Medical Research, which works under the nation’s health ministry, told Bloomberg TV on Friday.
Is it causing the record surge in infections in India?
Genome sequencing indicates the variant as a possible culprit. The average prevalence of the variant surged to as high as 52% of samples sequenced in April from almost nothing in January, according to website tracker outbreak.info, which uses data from global repository GISAID.
In some districts in Maharashtra state -- home to the nation’s financial hub Mumbai and epicenter of the current wave that’s currently under lockdown-like rules -- the prevalence of this variant was more than 60%, according to Anurag Agrawal, director of the state-run Council of Scientific and Industrial Research’s genomics institute that’s conducting sequencing. The B.1.617 was present in samples from about 10 Indian states and while the percentage may vary, it was expected to rise as “it has two critical mutations that make it more likely to transmit and escape prior immunity,” Agrawal said.
“We did the math -- we do believe that a lot of the increase in the reproduction number can be explained by these mutations,” Nithya Balasubramanian, the head of healthcare research at Bernstein India, told Bloomberg TV this week. “So, yes, the mutations are a big cause for worry.”
After slowly mapping virus genomes in recent months -- India did sequencing for less than 1% positive samples as of last month -- the country is now scrambling to cover lost ground. “We are attempting to do at least 5% of whatever samples are there,” said ICMR’s Mukherjee.
“It looks like that it is spreading faster than pre-existing variants,” said Rakesh Mishra, the Hyderabad-based director of the Centre for Cellular and Molecular Biology -- another Indian lab doing genome sequencing of Covid samples. “Sooner or later, it will become prevalent in the whole country, given the way it is spreading.”
Has it been found outside India?
This variant has been detected in at least 10 other countries, including the U.S., the U.K., Australia and New Zealand, according to the situation report on outbreak.info.
As of April 16, 408 sequences in the B.1.617 lineage have been detected of which 265 were found in India, the report shows. A surveillance report by the U.K. government said it has found 77 cases in England and Scotland so far, designating it as a “Variant Under Investigation.”
New Zealand has temporarily suspended arrivals of its citizens and residents from India due to the spike in the number returning with Covid. Brazil was also shunned as a Covid superspreader by its neighbors who were nervous about the virus strain next door.
India’s second wave -- given its size and rapid pace -- will worry other nations that have just about managed their own outbreaks after weeks of economy-devastating lockdowns.
Is it deadlier than other variants out there?
Researchers are still trying to figure that out. The features of the double mutant variant are under investigation, but the L452R mutation is well characterized in U.S studies, according to Agrawal. It increases viral transmission by around 20% and reduces antibody efficacy by more than 50%, he said.
Globally, three worrisome variants that have so far emerged in the U.K., South Africa and Brazil have caused particular concern. Studies suggest they are more contagious, and some evidence points to one of them being more deadly while another drives reinfections.
The double mutant strain, first found in India, has begun troubling virologists everywhere.
“The B.1.617 variant has all the hallmarks of a very dangerous virus,” William A. Haseltine, a former professor at Harvard Medical School wrote in Forbes on April 12. “We must do all that is possible to identify its spread and to contain it.”
Do vaccines work against it?
It’s hard to know for sure without adequate data and research. India is testing whether the new variants, including the B.1.617, are capable of “immune escape or not,” according to ICMR’s Mukherjee.
Immune escape refers to a pathogen’s ability to evade human bodies’ immunity response. This means antibodies created after vaccination or prior infection may not protect a person from getting infected. If the new India variant shows “immune escape” behavior, this would have deep ramifications for India’s vaccination program, which has picked up after a sluggish start and administered 117 million doses so far.
India has currently authorized three vaccines. Two of them are already in use while the third, Russia’s Sputnik V, was approved this week. India also fast-tracked approval for foreign vaccines this week. All of these efforts risk being jeopardized if the shots turn out to be less effective against this double mutation variant.
“It is one of the ones that’s on our radar, and in doing so, it means it’s on the radar of people around the world,” said Van Kerkhove.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.